Palvella Therapeutics, Inc. (NASDAQ:PVLA – Free Report) – Research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Palvella Therapeutics in a report issued on Monday, October 12th. HC Wainwright analyst A. Fein forecasts that the company will earn ($2.40) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $246.00 target price on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($6.40) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ Q2 2027 earnings at ($2.59) EPS, Q3 2027 earnings at ($4.16) EPS and Q4 2027 earnings at ($4.36) EPS.
Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.35).
View Our Latest Research Report on PVLA
Palvella Therapeutics Stock Performance
Shares of NASDAQ PVLA opened at $122.58 on Thursday. Palvella Therapeutics has a 52-week low of $68.96 and a 52-week high of $161.38. The firm has a 50 day moving average price of $146.74 and a 200 day moving average price of $134.32.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of PVLA. KBC Group NV bought a new stake in Palvella Therapeutics in the first quarter valued at approximately $28,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Palvella Therapeutics in the second quarter valued at approximately $35,000. Archer Investment Corp acquired a new stake in shares of Palvella Therapeutics in the second quarter valued at approximately $69,000. Quantbot Technologies LP bought a new position in shares of Palvella Therapeutics during the 2nd quarter worth approximately $71,000. Finally, State of Wyoming bought a new position in shares of Palvella Therapeutics during the 2nd quarter worth approximately $134,000. 40.11% of the stock is currently owned by institutional investors.
Insider Activity at Palvella Therapeutics
In related news, Director George Jenkins sold 7,174 shares of the company’s stock in a transaction on Tuesday, October 13th. The shares were sold at an average price of $130.36, for a total value of $935,202.64. Following the completion of the transaction, the director directly owned 139,790 shares of the company’s stock, valued at approximately $18,223,024.40. This represents a 4.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher Kiritsy sold 313 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $157.00, for a total value of $49,141.00. Following the transaction, the director owned 250 shares of the company’s stock, valued at approximately $39,250. This trade represents a 55.60% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 56,743 shares of company stock valued at $8,219,632. 17.20% of the stock is owned by corporate insiders.
Key Headlines Impacting Palvella Therapeutics
Here are the key news stories impacting Palvella Therapeutics this week:
- Positive Sentiment: HC Wainwright maintained its Buy rating and $246 price target. Although the firm lowered its earnings estimates, the target remains well above recent trading levels, reflecting continued confidence in Palvella’s longer-term opportunity. Palvella Therapeutics analyst coverage
- Neutral Sentiment: Palvella will present at the Chardan 10th Annual Healthcare Conference on October 20. Management’s fireside chat may provide updates on QTORIN 3.9% and the company’s rare-disease programs, but the announcement contained no new clinical or regulatory information. Palvella conference announcement
- Negative Sentiment: HC Wainwright substantially reduced its 2027–2030 EPS forecasts. Estimates now call for losses of $13.52 per share in 2027, $10.40 in 2028 and $4.84 in 2029. The 2030 profit estimate was cut to $5.82 from $19.10. The revisions imply a slower path to profitability and are the clearest fundamental pressure on PVLA.
- Negative Sentiment: Director George Jenkins sold 20,326 shares for approximately $2.69 million. The sales on October 12 and 13 reduced his direct position by roughly 13%. Both transactions were executed under a pre-arranged Rule 10b5-1 plan, which reduces their signaling value, but the size of the sales may still weigh on sentiment. Palvella SEC insider transaction filing
About Palvella Therapeutics
Palvella Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare and serious diseases. The company’s work centers on localized treatments intended to address conditions for which existing therapeutic options are limited.
Palvella’s lead investigational product is QTORIN 3.9%, a topical formulation of sirolimus designed to deliver the medicine directly to affected areas of the skin. The product is being developed for microcystic lymphatic malformations, rare vascular anomalies that can cause swelling, pain and disfigurement.
Recommended Stories
- Five stocks we like better than Palvella Therapeutics
- Swarm Economics: Can XTEND AI Robotics Deliver at Scale?
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
